Latest Medicinal Cannabis News

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Vitura Health Limited has acquired Candor Medical, a leading Australian medicinal cannabis clinic, for $5.9 million, significantly boosting its digital health platform and patient base.

Vitura Health has raised $5.1 million from prominent investor Professor Khalil Shahin, marking a significant step towards acquiring Candor Medical and accelerating its digital health expansion.

Cann Group Limited has negotiated an extension of its NAB loan maturity and deferred upcoming interest payments, providing crucial breathing room for its capital projects and working capital needs.

Wellnex Life Limited has announced a non-renounceable entitlement offer to raise approximately $22.1 million at $0.65 per share, supporting its planned AIM listing and strategic growth initiatives.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.

Althea Group Holdings has obtained Federal Court orders confirming the validity of past share sales despite previous failures to lodge required Cleansing Notices, paving the way for the reinstatement of its shares to trading.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Cann Group Limited reported a positive operating cash flow for Q2 2024, driven by an R&D tax credit refund, while ramping up production and navigating pricing pressures in the medicinal cannabis market.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

ECS Botanics reports a striking 339% quarter-on-quarter growth in its B2C sales, offsetting a slight dip in total revenue as it pivots to a hybrid B2B and B2C business model. The company’s record harvest and new product launches position it for a promising turnaround.